Payment overview · 2025
General Payments
$139.73
6 reported records · 4 companies
Healthcare provider profile · identity verified
Revan Maragiri, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BAY CITY, MI · NPI 1831162460
Verified facts
What the public records show
CMS Open Payments records show Revan Maragiri, M.D. received $139.73 in general payments during 2025 across 6 reported records.
Abbott Laboratories accounted for 44.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.95 | 44.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $38.80 | 27.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.27 | 14.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.71 | 13.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $99.77 | 5 |
| Long term medical supply or device loan | $39.96 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $39.96 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.80 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 533 | 156 |
| Losartan Potassium | Losartan Potassium | 430 | 122 |
| Metoprolol Tartrate | Metoprolol Tartrate | 345 | 95 |
| Metformin Hcl | Metformin Hcl | 261 | 66 |
| Lisinopril | Lisinopril | 197 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 172 | 44 |
| Naproxen | Naproxen | 171 | 56 |
| Simvastatin | Simvastatin | 159 | 37 |
| Famotidine | Famotidine | 153 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 145 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 62 |
| Furosemide | Furosemide | 134 | 41 |
| Omeprazole | Omeprazole | 133 | 43 |
| Tramadol Hcl | Tramadol Hcl | 132 | 21 |
| Gabapentin | Gabapentin | 115 | 31 |
| Clonazepam | Clonazepam | 106 | 23 |
| Sertraline Hcl | Sertraline Hcl | 97 | 20 |
| Nifedipine Er | Nifedipine | 96 | 27 |
| Potassium Chloride | Potassium Chloride | 96 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 93 | 24 |
| Eliquis | Apixaban | 91 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 27 |
| Allopurinol | Allopurinol | 84 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 18 |
| Alprazolam | Alprazolam | 68 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 11 |
| Jardiance | Empagliflozin | 63 | 20 |
| Mirtazapine | Mirtazapine | 61 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 11 |
| Ozempic | Semaglutide | 60 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 58 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 19 |
| Buspirone Hcl | Buspirone Hcl | 51 | 15 |
| Finasteride | Finasteride | 50 | 12 |
| Trazodone Hcl | Trazodone Hcl | 50 | 12 |
| Ibuprofen | Ibuprofen | 49 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 14 |
| Januvia | Sitagliptin Phosphate | 43 | 14 |
| Atenolol | Atenolol | 42 | 15 |
| Carvedilol | Carvedilol | 42 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | suppressed |
| Glimepiride | Glimepiride | 39 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | suppressed |
| Nitroglycerin | Nitroglycerin | 33 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Cephalexin | Cephalexin | 22 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 18 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 12 |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 15 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Colchicine | Colchicine | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $139.73 · 6 records | Abbott Laboratories | FARXIGA, FREESTYLE INSULINX, FREESTYLE LIBRE 3, MOUNJARO, Ozempic, Rybelsus | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error